Evidence on multimorbidity from definition to intervention: an overview of systematic reviews by Xu, Xiaolin et al.
Accepted Manuscript
Title: Evidence on multimorbidity from definition to
intervention: an overview of systematic reviews
Authors: Xiaolin Xu, Gita D. Mishra, Mark Jones
PII: S1568-1637(17)30012-0
DOI: http://dx.doi.org/doi:10.1016/j.arr.2017.05.003
Reference: ARR 764
To appear in: Ageing Research Reviews
Received date: 24-1-2017
Revised date: 9-5-2017
Accepted date: 9-5-2017
Please cite this article as: Xu, Xiaolin, Mishra, Gita D., Jones, Mark, Evidence
on multimorbidity from definition to intervention: an overview of systematic
reviews.Ageing Research Reviews http://dx.doi.org/10.1016/j.arr.2017.05.003
This is a PDF file of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that
apply to the journal pertain.
1 
 
Highlights 
 This overview identified 53 systematic reviews on various aspects of multi-morbidity 
including definition, measurement, prevalence, risk factors, health outcomes, clinical 
practice and medication (polypharmacy), and intervention and management. 
 Heterogeneity of topics, methods, and reporting has resulted in inconsistent findings 
among the included reviews.  
 However there is general agreement that further prospective research is needed, 
especially longitudinal cohort studies and randomized control trials, in order to 
provide more definitive evidence on multimorbidity. 
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ABSTRACT 
The increasing challenge of multiple chronic diseases (multimorbidity) requires more evidence-
based knowledge and effective practice. In order to better understand the existing evidence on 
multimorbidity, we performed a systematic review of systematic reviews on multimorbidity with 
pre-established search strategies and exclusion criteria by searching multiple databases and grey 
literature. Of 8006 articles found, 53 systematic reviews (including meta-analysis and qualitative 
research synthesis performed in some reviews) that stated multimorbidity as the main focus were 
included, with 79% published during 2013 to 2016. Existing evidence on definition, measurement, 
prevalence, risk factors, health outcomes, clinical practice and medication (polypharmacy), and 
intervention and management were identified and synthesised. There were three major definitions 
from three perspectives. Seven studies on prevalence reported a range from 3.5% to 100%. As six 
studies showed, depression, hypertension, diabetes, arthritis, asthma, and osteoarthritis were prone 
to be comorbid with other conditions. Four groups of risk factors and eight multimorbidity 
associated outcomes were explored by five and six studies, respectively. 27 studies evaluated 
interventions, which could be categorized into either organizational or patient-oriented, the effects 
of these interventions were varied. We were unable to draw solid conclusions from this overview 
due to the heterogeneity in methodology and inconsistent findings among included reviews. As 
suggested by all included studies, there is a need for prospective research, especially longitudinal 
cohort studies and randomized control trials, to provide more definitive evidence on multimorbidity. 
Keywords: multimorbidity; systematic review; definition; prevalence; risk factors; outcomes; 
polypharmacy; intervention 
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1. Introduction  
Age-associated multiple chronic diseases (multimorbidity) is a growing issue and poses a major 
challenge to health care systems around the world (Tarry-Adkins and Ozanne; World Health 
Organization., 2015). Dealing with multimorbidity is complex for both health care providers and 
researchers (Atun, 2015). Although research interest in multimorbidity is growing, for example, our 
previous research found an exponential growth of research outputs on multimorbidity in the past 
decade; a number of knowledge gaps in multimorbidity research need to be addressed (US 
Department of Health and Human Services., 2010). These knowledge gaps may include all aspects 
of multimorbidity. Healthy aging  is a World Health Organization (WHO) global health and 
research priority for 2016 to 2020 (Executive Board 134 A69/17., 2016; World Health 
Organization., 2015) 
Systematic reviews are recognized as the cornerstone of evidence-based health care (Pieper et al., 
2014). It is important to assess the gaps in existing evidence by synthesising these systematic 
reviews, so that valuable knowledge and effective interventions on multimorbidity may be 
identified and put into practice. We did a systematic review of systematic reviews to assess the 
present evidence on multimorbidity to answer: What do we know about the current evidence on 
multimorbidity research and practice, and where do we go in the future based on the implications of 
current evidence?  
2. Methods 
2.1 Review eligibility criteria and search strategy 
Inclusion criteria were: (1) review of primary studies by a systematic literature search; (2) the main 
focus of the article was on multimorbidity; (3) the subtopics can be broad, such as definition, 
epidemiology, outcomes, intervention, and intervention; (4) written in English; and (5) studies 
referring to humans. Studies whose contents primarily addressed refer to an index disease and its 
related comorbidity, such as diabetes and its comorbidities, were excluded. If studies included 
partial content about multimorbidity, we included them if we were able to extract relevant data.  
We performed a systematic literature search to identify all published systematic reviews on 
multimorbidity. PubMed, Embase, and Cochrane Database of Systematic Review were searched 
from inception to August 2016. Details on search strategies are included in Appendices 1-4. We 
also used a Google search to identify grey literature, and manually searched the Journal of 
Comorbidity for potential reviews.  
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2.2 Data extraction and evidence synthesis 
Two author (XX, MJ) conducted the searches, eligibility assessment, data extraction, evidence 
synthesis, and quality assessment. Regular study group meetings were held to review the process, 
and to resolve any discrepancies and questions (XX, GDM and MJ). For each systematic review, 
characteristics were extracted on the duration of included studies, author’s country, review types, 
topics, and number of included studies. Specific data extraction forms were developed for 
prevalence, outcomes and interventions.  
We did not perform meta-analysis because the heterogeneity and overlap of primary studies among 
some systematic reviews. Instead, we performed qualitative evidence synthesis in tables or narrative 
text based on the volume of evidence.  
2.3 Quality assessment 
We assessed methodologic quality of each included systematic review with the Assessment of 
Multiple Systematic Reviews (AMSTAR) tool (Shea et al., 2007).  The AMSTAR tool is a reliable 
and valid tool to assess both systematic reviews of randomized and non-randomized control studies 
(Pieper et al., 2014).  
2.4 Ethical issues 
The research used published data from secondary sources and did not involve any interactions with 
human subjects. Hence it is exempt from institutional review board (IRB) approval process.  
3. Results  
3.1 Overview of search results and quality assessment 
A total of 8006 systematic reviews were identified, of which 107 articles were included for full text 
screening, with 54 excluded for various reasons. The study selection process is presented in Figure 
1, and the excluded articles are listed in Appendix 5. The first review was published in 2004, and 79% 
(n=42) were published between 2013 and 2016. All of the reviews were in English, 51 were from 
Europe and North American, two were from China and India. All of the reviews were systematic 
reviews, five performed meta-analysis, and seven performed qualitative research synthesis, see 
Appendix 6.  
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Figure 1. PRISMA flow chart for overview of systematic review of multimorbidity. 
Of the included 53 systematic reviews, six reviewed definition and measurement, seven reviewed 
prevalence, nine reviewed disease clusters and patterns, five reviewed risk factors, nine reviewed 
outcomes, three reviewed clinical decision making, three reviewed clinical practice guidelines, 
eight reviewed medication, 11 reviewed intervention and management, and two reviewed inclusion 
multimorbidity in clinical and intervention trials and multimorbidity at the end of life (see Figure 2 
and Appendix 6).  
 
Figure 2. Summary of research topics on multimorbidity. The size of each rectangle for each topic 
in this tree map is proportional to the number of studies from all included systematic reviews. 
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The overall AMSTAR ratings was similar between the two independent reviews (intra-class 
correlation 0.91). Ratings ranged between 1 and 11 for each of the observers with a comparison 
between the two observers showing 87% ratings within 1 of each other and the remaining 13% 
within 2 of each other. Ratings by XX are presented in Appendix 7. As the AMSTAR tool was 
designed specifically for RCTs, the quality of reviews that performed meta-analysis with RCTs was 
high (average score was 8). However, the quality of reviews that performed qualitative research 
synthesis was generally low (average score was 4.4), because some items (e.g. the appropriate use 
of methods to combine findings of studies and assessment of the likelihood of publication bias) are 
not available for non-RCTs and qualitative research. The main methodological weaknesses were 
lack of 'a priori' design (protocol, ethics approval, or pre-determined/a priori published research 
objectives) and lack of a list of excluded studies.  
3.2 Definition and measurement  
Heterogeneity in definition and measurement of multimorbidity is the key issue in most included 
systematic reviews, which led to difficulties in results comparison and precluded meta-analysis. We 
detected two systematic reviews focused on definition (Le Reste et al., 2013; Willadsen et al., 2016), 
and five focused on measurement related topics (Diederichs et al., 2011; Holzer et al., 2014; Huntley 
et al., 2012; Willadsen et al., 2016; Zullig et al., 2016).  
Three major definitions were detected from three major perspectives: epidemiology and public health, 
long term care and family medicine in primary care, and clinicians and patients in daily clinical 
practice (Table 1). Each of the definitions has strengths and limitations. The WHO definition is simple 
and easy to implement and was commonly used by most included studies. The other two definitions 
are comprehensive, yet more relevant to clinical practice for GPs and patients.  
Most studies included chronic conditions in the definition, some studies included acute conditions (Le 
Reste et al., 2013), but inclusion of these conditions is undesirable as they inflate multimorbidity rates 
unnecessarily (Salive, 2013). However, other fundamental determinates: biopsychosocial factors and 
somatic risk factors, coping strategies of the patient, burden of disease, health care consumption, 
disability, quality of life, social network, and health outcome were suggested to be considered in long 
term care and family medicine (Le Reste et al., 2013). 
Table 1 
Definition of multimorbidity from different perspectives.  
Sources  Perspective  Definition or main suggestion Strengths  Limitations  
(World 
Health 
Organization.
, 2015) 
Epidemiology 
and public 
health 
The co-occurrence of two or 
more chronic medical conditions 
in one person 
Easy to use in 
research for 
epidemiological 
and disease burden 
Is not sufficiently 
clear for a 
particular 
purpose, and 
could lead to 
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numerous 
interpretations  
(Willadsen et 
al., 2016) 
Clinicians 
and patients 
in daily 
clinical 
practice 
The role of diseases, risk factors, 
symptoms, and severity need to 
be included in the definition 
More relevant for 
daily clinical work, 
and has a better 
capacity for 
capturing the 
patient’s 
perspective 
(symptoms) 
Very complicated, 
especially for the 
situation of 
compression 
among studies 
(Le Reste et 
al., 2013) 
Long term 
care and 
family 
medicine in 
primary care 
Multimorbidity is defined as any 
combination of chronic disease 
with at least one other disease 
(acute or chronic) or 
biopsychosocial factor 
(associated or not) or somatic 
risk. Any biopsychosocial factor, 
any somatic risk factor, the 
social network, the burden of 
diseases, the health 
consumption, and the patient’s 
coping strategies may function 
as modifiers (of the effects of 
multimorbidity). Multimorbidity 
may modify the health outcomes 
and lead to an increased 
disability or a decreased quality 
of life or frailty 
Brings into focus 
the possible 
outcomes of 
multimorbidity 
(health outcomes, 
disability, quality of 
life, frailty) to keep 
physicians alert to 
those patients’ 
needs 
Including acute 
conditions makes 
the use of this 
definition more 
complicated, 
because acute 
conditions inflate 
multimorbidity 
rates 
unnecessarily 
 
Studies on measurement of multimorbidity focused on the role of cut-points in the definition (Holzer 
et al., 2014; Willadsen et al., 2016), instruments to assess the level and outcome of multimorbidity 
(Diederichs et al., 2011; Huntley et al., 2012), and the role of complexity in the definition (Zullig et 
al., 2016). 
The prevalence of multimorbidity primarily depends on how many conditions to include. 37% of 
studies used a cut-point of two or more conditions to a range of 4-147 different conditions in the 
definition (Willadsen et al., 2016). The cut-points of two or three chronic conditions provides 
essentially the same information on prevalence (Holzer et al., 2014). A list of at least 12 chronic 
diseases, is required in estimating stable prevalence rates (Fortin et al., 2012). 
Multimorbidity indices are usually used to predict the disease severity and health outcome at the 
individual level. The most commonly used instruments were Charlson index, Chronic Disease Score, 
ACG System, and Cumulative Index Illness Rating Scale (Diederichs et al., 2011; Huntley et al., 
2012). When choosing instruments we need to consider the type of date available and specific 
outcomes (Huntley et al., 2012). 
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Complexity is another factor that poses challenges for definition of multimorbidity in research 
(Grembowski et al., 2014). To improve care, current models for multimorbidity patient’s needs to 
include social and medical components to address the spectrum of factors driving complexity (Zullig 
et al., 2016). Zulling and colleagues identified a Cycle of Complexity model, which strengthened the 
weakness of former complexity models in five aspects: contextual factors, dynamics of complexity, 
patients’ preference, acute health shocks, and resilience. 
3.3 Epidemiology 
3.3.1 Prevalence  
There were seven systematic reviews (Fortin et al., 2012; Hu et al., 2015; Marengoni et al., 2011; Pati 
et al., 2015; Salive, 2013; Van Den Brink et al., 2013; Violan et al., 2014) focused on the prevalence 
of multimorbidity. Detailed information extracted from the systematic reviews is summarized in Table 
2.  
Of the seven included systematic reviews, four were from Europe and North American countries, one 
from China, and one from India and Bangladesh. Studies methods included cross-sectional studies and 
various national and local medical databases. The number of conditions varied from two to many, 
with prevalence from 3.5% (at age 75) to 100% (at mean age 85). The prevalence increased with the 
increase of age, an S-shape curve for prevalence by age was detected in the general population (Fortin 
et al., 2012), and the prevalence in older persons is nearly 100% (Fortin et al., 2012; Marengoni et al., 
2011; Van Den Brink et al., 2013). However, the results vary widely among studies, and no meta-
analysis was performed as the heterogeneity was large in terms of definition, sample, and methods 
among primary studies (Fortin et al., 2012; Pati et al., 2015). 
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Table 2 
Characteristics of systematic review concerning prevalence of multimorbidity.  
Study  
Design & 
Samples  
Duration  Countries  Settings  Age  
Number of 
conditions 
Results  
Quality of 
included studies  
(Marengon
i et al., 
2011) 
12 cross-
sectional 
1998-2009 Dutch, US, Canada, 
Australia, Sweden, Spain 
General 
population, 
community, 
hospital and 
institution based 
people 
All  ≥2-4 20.3%-98 %( 20-30% when the 
whole population was considered, 
55-98% when older persons were 
included) 
NA 
(Fortin et 
al., 2012) 
21  
NA study 
types 
 
1989-2010 Netherlands, UK, 
Canada, Australia, 
Greece, US, Israel, 
Finland, Italy, Ireland, 
Spain  
 
General 
population and 
primary care 
All  From 2 to 
many  
An S-shape curve for prevalence by 
age, with lower estimates before 40 
years (< 20%) and then a steep 
increase in prevalence followed by 
a plateau at about 70 years(around 
75%), the prevalence at age 75 in 
primary care is 3.5%-98.5% and the 
general population is 13.1-71.8% 
All were good 
quality 
(Strengthening 
the Reporting of 
Observational 
Studies in 
Epidemiology, 
STROBE) 
(Salive, 
2013) 
17 self-
reported 
medical 
database, 
recruited 
cohort 
1989-2012 US, Israel, Finland, 
Netherlands, Italy, 
Canada, Ireland, 
Australia, Germany, 
Sweden, Spain 
National sample 
survey, medical 
claim data, cohort 
study, clinical 
assessment  
All  From 2 to 6-
many 
13% at age of 10 to 83% at age ≥75 
 
NA 
(Van Den 
Brink et 
al., 2013) 
1 cross-
sectional  
 2009 Norway Long-term care 
facilities 
85 6-33 Nearly 100%  
 
Poor quality 
(Pati et al., 
2015) 
13 cross-
sectional 
2002-2015 India, Bangladesh Community based 
(urban and rural) 
≥18 From 2 to 7-
16 (1 study 
did not list) 
4.5%-83% Good quality 
(STROBE) 
(Hu et al., 
2015) 
9 cross-
sectional 
2002-2011 China  Community based  ≥60 From 2 to 7-
14 
6.4%-76.5% 2 low risk, 2 
high risk, 5 
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unclear 
(STROBE) 
(Violan et 
al., 2014) 
39 
21 cross-
sectional, 
18 cohort 
1984-2013 Italy, UK, Australia, 
Spain, Canada, Ireland, 
Germany, US, Sweden, 
Netherlands, Greece, 
Switzerland, Spain 
Health records, 
interview, claims 
All  From 2 to 5-
335 
12.9%-95.1% High in most 
studies 
(STROBE) 
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3.3.2 Disease clusters and patterns  
Knowledge about the patterns, specific diseases combinations, and common diseases of 
multimorbidity will provide essential information for guideline development, clinical management, 
and public intervention. Three disease patterns (cardiovascular and metabolic disease, mental health 
related problems, and musculoskeletal disorders) were identified among 97 patterns composed of two 
or more diseases and 63 patterns were composed of three or more diseases (Prados-Torres et al., 
2014). Four statistics methodologies were detected to determine patterns: cluster analysis techniques, 
factor analysis, the observed-to-expected ratio, and multiple correspondence analyses (Prados-Torres 
et al., 2014).  
Sinnige and colleagues identified 165 combinations of two diseases from 63 diseases in Europe and 
North America. Of the combinations, depression was most commonly clustered, followed by 
hypertension, diabetes, and coronary artery disease (Sinnige et al., 2013).  An Australian elderly 
population based systematic review found that over 50% of the elderly patients with arthritis also had 
hypertension, followed by CVD, dyslipidemia, diabetes, and mental health problems; whereas 60% of 
elderly patients with asthma reported arthritis followed by CVD and diabetes (Caughey et al., 2008). 
Certain disease combinations may have greater risk for certain types of health outcomes (France et al., 
2012), such as chronic respiratory disease, congestive heart failure, and diabetes may result in higher 
physical decline than other combinations. 
Six systematic reviews reported common diseases in the included studies (Caughey et al., 2008; 
Diederichs et al., 2011; Hu et al., 2015; Pati et al., 2015; Sinnige et al., 2013; Willadsen et al., 2016). 
The detailed information extracted from systematic reviews are summarized in Table 3 and Appendix 
8. 
Table 3 
Summary of disease patterns, disease combinations, and common diseases in multimorbidity.   
Disease patterns  Disease combinations   Common diseases  
 Cardiovascular and metabolic 
diseases 
 Mental health related problems 
 Musculoskeletal disorders 
 Depression comorbid with 
other 8 conditions (e.g. 
hypertension, arthritis, 
diabetes) 
 Hypertension comorbid with 
other 6 conditions (e.g. 
osteoarthritis, diabetes, cancer) 
 Diabetes comorbid with other 6 
conditions (e.g. hypertension, 
coronary artery disease) 
 Arthritis comorbid with 
hypertension, CVD, 
dyslipidemia, diabetes,  and 
mental health problems 
 Diabetes  
 Heart disease 
 Cancer 
 Hypertension 
 Depression 
 COPD 
 Stroke 
 Arthritis/ osteoarthritis 
 Osteoporosis 
 Asthma 
 Gastrointestinal problems 
 Heart failure  
 Dementia 
 Hearing problems 
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 Asthma comorbid with 
arthritis, CVD, and diabetes 
 Osteoarthritis comorbid with 
CVD and/or metabolic 
conditions  
 Vision problems 
 Unitary problems 
 Thyroid diseases 
 
3.2.3 Risk factors  
Five systematic reviews (Boutayeb et al., 2013; France et al., 2012; Marengoni et al., 2011; Pati et al., 
2015; Violan et al., 2014) summarized risk factors for multimorbidity (Table 4). Identified risk factors 
for multimorbidity may be categorized into four groups: biomedical and individual factors, health 
behaviours, socioeconomic characteristics, and social and environment factors. Although most studies 
suggested low economic status and lower education were risk factors for multimorbidity, some studies 
reported opposite findings, such as high income as a risk factor in LMICs (Pati et al., 2015). 
Table 4 
Summary of risk factors for multimorbidity. 
Biomedical and 
individual factors  
Socioeconomic 
characteristics 
Social and environment 
factors  
Health behaviours  
 Aging 
 Women 
 High number of 
previous disease 
 Negative life events  
 External health locus 
of control 
 Mental disorders 
 Lower social 
economic status 
 High income Group 
(LMICs) 
 Lower education 
 Less social networks 
 Fully dependent 
 Unemployed/retired 
 Living in urban 
(LMICs) 
 Tobacco 
 Overweight and obese 
 high risk waist hip 
ration 
Inactive physical 
actives  
 
3.2.4 Multimorbidity associated outcomes  
Six systematic reviews addressed seven types of multimorbidity associated outcomes (one studies 
summarized more than one outcomes) (Table 5). Of the six reviews, one assessed the risk of mortality 
(Marengoni et al., 2011), two assessed disability and functional decline (Marengoni et al., 2011; Ryan 
et al., 2015), two evaluated the quality of life (Fortin et al., 2004; Marengoni et al., 2011), three 
focused on healthcare use and cost (France et al., 2012; Lehnert et al., 2011; Marengoni et al., 2011),  
one evaluated the “Do Not Resuscitate” orders (DNR) decision making process (de Decker et al., 
2014), and one focused on patients safety (Panagioti et al., 2015).  
The evidence from these systematic reviews demonstrates the significant association between 
multimorbidity and various adverse outcomes with few controversial results. Some reviews evaluated 
the relationship between number of diseases, disease combinations and outcomes (Fortin et al., 2004; 
France et al., 2012; Marengoni et al., 2011). One review demonstrated multimorbidity could predict 
future functional decline, with greater decline in patients with higher numbers of conditions and 
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greater disease severity (Ryan et al., 2015). Certain combinations of chronic conditions are related to 
certain outcomes, for example, chronic respiratory disease, congestive heart failure, and diabetes 
presented a greater risk for physical decline than others (France et al., 2012).  
The role of multimorbidity in the risk stratification tools to predict negative outcomes is important but 
infrequently used and assessed. Alonso-Morán and colleagues conducted a qualitative synthesis from 
36 studies and found that most risk stratification tools were developed to predict hospital admission or 
readmission, with some tools (e.g. the Charlson Comorbidity Index) dealing with multimorbidity 
(Alonso-Morán et al., 2015). 
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Table 5 
Summary of included systematic reviews on multimorbidity with different outcomes. 
Study  
Countries 
Study & 
duration  
Samples  Population  Outcomes  Outcome scales Results  
Quality of 
included 
studies 
(Marengoni 
et al., 2011) 
Finland, Italy, 
Netherlands, 
Australia, 
Sweden  
2001-2010 
5 
4 self-report 
with others, 
1 clinical 
and medical 
record  
Community 
and  
veterans and 
war widows 
Age ≥65 
Mortality  Number of years mortality  Significant results were found on the 
effect of multimorbidity on mortality, 
as an increasing number of coexisting 
diseases was significantly related to 
an increasing risk of mortality in 
some studies 
NA 
(Marengoni 
et al., 2011) 
Canada, US, 
Spain, UK, 
Sweden,  
2004-2009 
5 
3 cross-
sectional 
2 
longitudinal  
Community 
dwellers, 
Residential 
households 
and 
institutional 
Age ≥18 
Disability 
and 
functional 
decline 
Physical component summary 
score SF-36, physical function 
measured with the SF-12, 
physical activity levels, 3-year 
functional decline, impaired 
functioning 
An increasing number of diseases 
were consistently associated with 
increasing odds or risk for disability 
NA 
(Ryan et al., 
2015) 
Canada, US, 
Germany, Italy, 
Spain, UK, 
Australia, India, 
turkey, Sweden, 
Netherlands,  
1999-2014 
37 
28 cross-
sectional, 9 
cohort 
Community-
dwellings, 
Age ≥18 
Functional 
decline 
EQ-5D, SF-36, AIMS2, SPPB, 
four minute walking speed 
score, ALDs and IALDs, CDC 
HRQOL-4, hand grip test, 
multi-dimensional functional 
assessment questionnaire 
(OARS), standardised rapid 
disability rating scale-2, Barthel 
index, Friend’s criteria, 
Groningen activity restriction 
scale, FDI 
Multimorbidity predicts future 
functional decline, with greater 
decline in patients with higher 
numbers of conditions and greater 
disease severity  
Overall good 
quality 
(Cochrane 
Tool for the 
Assessment 
of Bias) 
(Fortin et al., 
2004) 
US, 
Netherlands, 
Sweden 
1993-2003 
7 
cross-
sectional and 
longitudinal  
Ambulatory, 
family 
medicine  
Age ≥18 
Quality of 
life  
SF-36, European organization 
for research of cancer quality of 
life questionnaire 
(EORTCQOL), SF-20, modified 
An inverse relationship between the 
number of medical conditions and 
QOL or HRQOL, multimorbidity 
mostly affects physical dimensions of 
Met the 
criteria (self-
devised 
evaluation 
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Nottingham health 
profile(NHP), quality of well-
being scale(QWB)  
QOL or HRQOL, social and 
psychological dimensions may be 
affected in patients with 4 or more 
diagnoses 
criteria scale) 
(Marengoni 
et al., 2011) 
Australia, 
Canada, Hong 
Kong(China), 
Spain   
2005-2009 
6 
5 cross-
sectional, 1 
longitudinal  
General 
population, 
veterans and 
war widows 
Age ≥20 
Quality of 
life 
SF-36, Indice de Dètresse 
Psychologique de l’Enquete 
Santé Québec, SF-12 
Multimorbidity was associated with 
depression, distress and generally 
with pool quality of life 
NA 
(Lehnert et 
al., 2011) 
US, Sweden, 
Germany, 
Canada, Italy, 
Spain, South 
Korea, 
China(Hong 
Kong) 
1992-2009 
35 
30 cross-
sectional, 3 
cohort, 2 
cross-control 
Hospital and 
community  
Age ≥55 
Health care 
utilization, 
health care 
cost 
Physician use, hospital use, 
pharmaceuticals, total health 
care costs, out-of-pocket 
payment 
A positive association between 
multimorbidity and health care 
utilization and cost, use/costs 
significantly increased with each 
additional condition 
NA 
(Marengoni 
et al., 2011) 
US, Australia, 
Germany, 
Sweden  
2002-2009 
8 
5 cross-
sectional, 1 
longitudinal 
Residents 
from 
primary 
healthcare 
and hospitals   
All age 
Health care 
utilization  
Hospitalization, complications, 
care needs, expenditures, 
learning self-managing diseases 
and medication 
The number of diseases was 
significantly associated with the 
number of prescriptions, referrals, 
hospital admissions and expenditures 
NA 
(France et 
al., 2012) 
US, Netherlands  
1994-2004 
3 cohort  Primary 
health care 
 
Health care 
utilization, 
health care 
cost 
Number/rate of consultations 
and episodes of disease, patient 
visits and charges, severity of 
disease 
Patients with multimorbidity had 
higher healthcare utilisation than 
those with only a single condition. 
Increasing multimorbidity 
predicted higher healthcare charges in 
an outpatient setting and an increased 
likelihood of inpatient admission 
Good quality 
(STROBE) 
(de Decker 
et al., 2014) 
NA 
1986-2010 
22 
18 cross-
sectional 
4 cohort 
Inpatients in 
dialysis 
centre, 
intensive 
“Do Not 
Resuscitate
” orders 
(DNR) 
Advance medical directives to 
withhold cardiopulmonary 
resuscitation during cardiac 
arrest 
DNR orders were positively 
associated with multimorbidity, and 
confirmed by further meta-analysis 
(OR=1.25), especially with three 
Met the 
criteria 
(STROBE, 
CONSORT) 
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care unit, 
emergency 
or burn 
department 
Age from 
60-86.5 
years  
morbidities, this association depends 
on the types of morbidity, cognitive 
impairment, cancer and stroke was 
significantly associated with the 
decision of DNR 
(Panagioti et 
al., 2015) 
US, Australia, 
Germany, 
Spain, Canada, 
Netherlands, 
Italy, Ireland, 
UK, Norway, 
Algeria, 
Bahrain, brazil, 
Sweden, Japan, 
China 
2004-2015 
75 
31 cross-
sectional, 32 
retrospective 
cohort, 8 
prospective 
cohort, 3 
case control 
and 1 trail 
General 
population, 
primary 
care, 
outpatients 
Age from 38 
to 80 
Patient 
safety 
incidents 
Active patient incidents 
(adverse drug events, medical 
complications), precursors of 
safety incidence (prescription 
errors, medication non-
adherence, poor quality of care 
and diagnostic errors) 
The association between 
multimorbidity and patient safety is 
complex, and varies by type of 
multimorbidity and type of safety 
incident. Meta-analysis demonstrated 
that physical-mental multimorbidity 
was associated with an increased risk 
for 'active patient safety incidents' 
and 'precursors of safety incidents'. 
Physical multimorbidity was 
associated with an increased risk for 
active safety incidents but was not 
associated with precursors of safety 
incidents 
Generally 
low (The 
Effective 
Public 
Health 
Practice 
Project 
instrument) 
SF-36: Short-Form-36 Health Survey; SF-20: Short-Form-20 Health Survey; SF-12: Short-Form-12 Health Survey; QOL: Quality Of Life; HRQOL: Health Related Quality 
Of Life; EQ-5D; AIMS2: arthritis impact measurement scale 2; FDI: functional dependency index; SPPB: short physical performance battery; CONSORT: Consolidated 
Standards of Reporting Trials; GRADE: Grading of Recommendations, Assessment, Development, and Evaluation
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3.4 Clinical practice and medication   
3.4.1 Clinical decision making with multimorbidity 
Clinical decision making with multimorbidity requires complex communications and collaborations 
among generalists, specialists, pharmacists, nurses, and patients. Better understanding of roles in the 
process of decision making, especially those of patients’, may be useful for clinical decisions and 
interventions development (Sinnott et al., 2013). 
Fraccaro and colleagues evaluated the current state of clinical decision systems (CDS) for 
multimorbidity and found that generalist doctors were the main decision makers, yet there were no 
studies referring to patients in the decision-making process or to patient self-management. There were 
no rigorous evaluations of usability or effectiveness of the CDS systems reported (Fraccaro et al., 
2015). Sinnott and colleagues reviewed 275 general practitioners’ perspectives on the management of 
patients with multimorbidity, and identified four difficulties: disorganization and fragmentation of 
healthcare, the inadequacy of guidelines and evidence-based medicine, challenges in delivering 
patient-centred care and barriers to shared decision-making (Sinnott et al., 2013). Mangin and 
colleagus examined current tools to assess patient treatment priorities and preferences with 
multimorbidity, only two studies use questionnaires (control preference scale and priority) to ask 
patients priorities on which outcome was more important to them, and their preferences on decision-
making (Mangin et al., 2016).  
3.4.2 Clinical practice guideline 
Evidence-based clinical practice guidelines are important tools for medical care and disease 
management. However, the traditional guidelines focused on single diseases with limited 
recommendations for multimorbidity (Lugtenberg et al., 2011; Wyatt et al., 2014). Lugtenberg and 
colleagues assessed the extent that guidelines addressed comorbidity by systematic analysis of 
guidelines focusing on four highly prevalent chronic conditions: chronic obstructive pulmonary 
disease, depressive disorder, diabetes mellitus type 2, and osteoarthritis (Lugtenberg et al., 2011). Of 
20 included guidelines published between 2005 and 2009 from North America, Europe, Singapore, 
Australia and New Zealand, 17 (85%) addressed the issue of comorbidity and 14 (70%) provided 
specific recommendations on comorbidity. However, of the 59 comorbidity related recommendations 
provided, only 8 (14%) addressed the discordant comorbidities (i.e. they are not directly related in 
their pathogenesis or management and do not share an underlying predisposing factor), and 73% of 
the recommendations were not adequately translated into the guidelines. 
Most guidelines did not take into account patients with multimorbidity. Wyatt and colleagues 
systematically examined the current clinical practice guidelines for patients with type 2 diabetes 
mellitus, and of the 28 eligible guidelines, only 8 (29%) incorporated the impact of multimorbidity 
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(Wyatt et al., 2014). This study suggested clinical practice guidelines for one chronic disease should 
consider the context of patients with multimorbidity. Young and colleagues systematically reviewed 
the clinical practice guidelines of Australia from 2006 to 2014, and only identified 13 patient-
preference recommendations and consumer-engagement processes (Young et al., 2015). Of these, 12 
included at least one core patient-preference recommendation, 10 used consumer-engagement 
processes including participation in development groups (7 guidelines) and reviewing drafts (10 
guidelines), but more practical details are required. 
3.4.3 Medication (polypharmacy) 
Multimorbidity usually involves multi-drug therapy (polypharmacy). Seven reviews were identified 
on medication use (with some of them focused on more than one topic simultaneously). Four studies 
focused on definition (Doos et al., 2014; Fulton and Allen, 2005; Jokanovic et al., 2015; Patterson 
Susan et al., 2014), two summarized prevalence of polypharmacy (Fulton and Allen, 2005; Jokanovic 
et al., 2015), one examined the polypharmacy patterns (Doos et al., 2014), two assessed risk factors 
(Fulton and Allen, 2005; Jokanovic et al., 2015), one examined the relationship between 
polypharmacy and outcomes (Fried et al., 2014),  and three assessed intervention to improve 
appropriate use and adherence to medicine (George et al., 2008; Patterson Susan et al., 2014; 
Williams et al., 2008). The detailed evidence is summarized in Table 6.   
Very few studies have investigated associations between specific patterns of multimorbidity and 
related multi-drug therapy in family practice. For instance, a systematic review focused on six 
common chronic conditions- diabetes, cardiovascular disease, cerebrovascular disease, chronic 
obstructive pulmonary disease, osteoarthritis, and depression- identified few studies on the 
relationship between multimorbidity and prescribed multiple drug therapy (Koch et al., 2015).  This 
study highlighted the combination of chronic conditions and depression is associated with suboptimal 
drug treatment in multiple drug therapy. 
Table 6 
Summary of the evidence on medication (polypharmacy) for multimorbidity.  
 Evidence  Notes  
Definition  
 Polypharmacy was often defined by two categories: number of 
medications and whether clinically indicated 
 the concomitant ingestion of 4 or more medications 
 5 or more medications in long term care facilities (LTCF) 
 the specific use of two or more drugs for two or more 
conditions in an individual (multi-drug therapy) 
 the use of medications that are not clinically indicated in 
clinical practice  
European studies defined 
polypharmacy according to 
the number of medications 
taken, whereas the studies 
conducted in the United 
States defined polypharmacy 
according to whether a 
medication was clinically 
indicated  
Prevalence   
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 Prevalence varied among different definitions, sample size, and 
settings 
 up to 91%, 74%, and 65% of residents were taking more than 
5, 9, and 10 medications, respectively in LTCF 
 ranged from 5% to 78% in patient populations 
 
Patterns   
 The combination of chronic conditions and depression is 
associated with suboptimal drug treatment in polypharmacy 
 
Very few studies have 
investigated association 
between multimorbidity and 
polypharmacy  
Risk factors  
  older age and women 
 diseases 
o comorbidity including circulatory diseases, endocrine and 
metabolic disorders and neurological motor dysfunctioning 
o cognitive impairment 
 medications 
o number of medications 
o medication without a clear indication 
 access to health services 
o number of visits to a primary care physician per year 
o recent hospital discharge 
o length of stay in the LTCF 
 disability in activities of daily living 
 
Health outcomes   
 The evidence was mixed, with some studies demonstrating an 
association between polypharmacy and falls, falls risk factors, and 
fall-related injury; adverse drug events, hospitalization, mortality, 
and a variety of measures of symptoms and physical and 
cognitive function 
The results from this review 
provide sufficient preliminary 
evidence to support RCTs in 
this research area 
Interventions  
 The following interventions were used for improving adherence 
and appropriate use  
 pharmacist- led medication review 
 group and individual education  
 individualized medication cards 
 behavioural strategies 
 simplified medication regimens  
 information and communication technology (ICT): email or 
telephone assessment and education 
 computer decision support (CDS) 
Psychosocial interventions 
engaging people in 
medication self-management 
offer potential for improved 
patient outcomes in complex 
diseases 
 
 
3.5 Intervention and management  
A total of nine systematic reviews were identified on intervention for multimorbidity. Considering 
most of the included interventions involved multiple model types and were named arbitrarily (de 
Bruin et al., 2012; Hopman et al., 2016; Smith Susan et al., 2016), we have used the Cochrane 
Effective Practice and Organisation of Care (EPOC) categorization of these interventions (Smith 
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Susan et al., 2016).  Of the 14 included interventions, seven were categorized into organizational 
(Bleich et al., 2015; Crowe et al., 2016; Lupari et al., 2011; Rydwik et al., 2004; Smith Susan et al., 
2016), five were primarily patient-oriented (Bleich et al., 2015; Dennis et al., 2013; Quiñones et al., 
2014; Smith Susan et al., 2016), and two focused on both (de Bruin et al., 2012; Hopman et al., 2016). 
Although the overall results from included interventions were mixed, some improvement in clinical, 
satisfaction, and health services use and cost outcomes were detected from both organisational and 
patient-oriented interventions.  
As Table 7 shows, various measurement indicators were used to evaluate the effectiveness of 
interventions. Of 27 included studies, all of the process measures were disease-specific, with some 
non-disease-specific measures (functional outcomes, healthcare utilisation and patient- rated measures) 
also identified (Pillay et al., 2014). 
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Table 7 
Summary of evidence examining interventions on multimorbidity.   
Review   
Countries 
& 
Study  
duration  
Samples  
Participant 
and settings   
Intervention
*
  Components of intervention Results  
Quality of 
included 
studies 
(Bleich 
et al., 
2015) 
US 
2008-2014 
3 
2 RCTs, 1 
case study 
Hospital or 
medical centre 
based  
Chronic disease 
self-management 
(patient-oriented)  
Provide information to patients and 
engage them in actively managing 
their chronic conditions  
Improvement in clinical 
outcomes (mortality, 
functional status, and pain) 
NA 
(Smith 
Susan et 
al., 2016) 
US, UK, 
Canada 
1999-2015 
6 RCTs 
 
Primary care 
and 
community 
settings 
 
Patient-oriented 
Self-management 
(patient-oriented) 
Diet and physical activity 
intervention with self-management 
support, OPTIMAL support course, 
multicomponent home intervention 
(the ABLE programme), “Making the 
most of your healthcare”, chronic 
diseases self-management 
programme, LIFE intervention  
Mixed results, that do not 
suggest patient-oriented 
interventions are generally 
effective; one study reported 
functional capacity and 
activity participation may be 
effective; another reported a 
reduction in mortality at 
longer-term follow up 
Overall 
quality was 
good 
(Cochrane) 
(Bleich 
et al., 
2015) 
US 
2008-2014 
7 
6 RCTs, 1 
quasi-
experimental 
Hospital or 
medical centre 
based  
Disease 
management 
(patient-oriented) 
Provide patients with information 
about their chronic conditions in 
writing or telephone 
Improvement in patient 
satisfaction, clinical, and 
health care use and cost 
outcomes 
NA 
(Bleich 
et al., 
2015) 
US 
2008-2014 
14 
3RCTs, 9 
quasi-
experimental, 
1 case-control, 
1 cohort 
Home, 
community, 
and hospital 
based 
All age  
Care and case 
management 
(organisational) 
Nurse or social workers help patients 
and their families to assess problems 
Improvement in patient 
satisfaction, clinical outcomes 
and successful health care use 
and costs 
NA 
(Smith 
Susan et 
al., 2016) 
US, UK, 
Canada 
2000-2015 
12 RCTs 
 
Primary care 
and 
community 
settings 
 
Case management 
and coordination 
of care or the 
enhancement of 
skill mix in 
UPBEAT intervention, integrated 
care, Guide Care programme, 
COINCIDE collaborative care model, 
APTCare intervention, TEAMcare 
intervention, WISE intervention, 
Little or no difference in 
clinical outcomes, mental 
health outcomes improved 
and modest reductions in 
mean depression scores for the 
Overall 
quality was 
good 
(Cochrane) 
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multidisciplinary 
(organisational) 
pharmaceutical care plan, cognitive 
behavioural therapy programme, 
TrueBlue collaborative care model, 
senior care connections intervention, 
home telehealth 
comorbidity studies that 
targeted participants with 
depression, a small 
improvement in patient-
reported outcomes, little or no 
difference to health service 
use, may slightly improve 
medication adherence, slightly 
improves patient related health 
behaviours, and probably 
improves provider behaviour 
in terms of prescribing 
behaviour and quality of care, 
cost data were limited 
(Lupari 
et al., 
2011) 
US, UK 
1996-2008 
8 
7 quantitative 
design and /or 
mixed 
approach, 1 
qualitative 
study 
Home based,  
Older patients  
Nurse-led, home 
based 
management 
(organisational) 
Hospital resources used 
(hospital readmission rates and 
lengths of stay), patients (health-
related quality of life, satisfaction and 
mortality), caregiver (satisfaction, 
carer strain or 
burden), cost-effectiveness metrics 
(from the perspective of the 
NHS payer) 
Access to car management 
services had a positive impact 
on the patient (health-care 
related quality of life, 
satisfaction and mortality), the 
carer (satisfaction, carer strain 
or burden) and the healthcare 
staff (workload) 
NA 
(Bleich 
et al., 
2015) 
US 
2008-2014 
1 case control Long-term 
care  
Age ≥65 
Nursing home 
(organisational)  
Primary care provided by an 
advanced-practice nurse or physician 
assistant 
Significant improvement in 
clinical, health care use and 
cost outcomes  
NA 
(Bleich 
et al., 
2015) 
US 
2008-2014 
1 quasi-
experimental  
Academic 
medical centre 
 
Transitional care 
(organisational) 
Facilitate smoother, safer, and more 
efficient transitions from hospital to 
the next site of care 
No significant improvement in 
clinical, health care use and 
cost outcomes 
NA 
(Crowe 
et al., 
2016) 
US, UK, 
Australia 
1999-2013 
12 
5 RCTs, 4 
open-label 
studies, 1 
concurrent 
Home based  
Age from 65 
to 78.5 
Transdiagnostic 
health 
management 
(organisational) 
CDSM, home-based 
interventions(care co-ordination via 
distance monitoring, multicomponent 
intervention ), community-based 
intervention(fitness programme with 
Structured transdiagnostic 
health management 
interventions may be clinically 
effective for older people with 
multimorbidity. Ten studies 
2 with a low 
risk of bias, 
4 with 
unclear risk 
bias, 6 with 
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controlled 
cohort study, 1 
case control 
study, 1 quasi-
experimental 
study 
nutritional counselling and weight 
management, Health Habits Program, 
generic self-management programme 
“Moving On”), service level 
interventions(inter-disciplinary 
collaborative practice intervention, 
intervention practice with an 
intensive self-management education 
package) 
reported statistically 
significant improvements in 
health outcomes, three studies 
identified some statistically 
significant reductions in health 
services utilization 
high risk 
bias 
(Cochrane) 
(Quiñone
s et al., 
2014) 
US, Spain, 
China, 
Netherlands 
1999-2007 
4 RCTs Community 
based 
Age from 57 
to 68 
Educational 
groups visits 
(patient-oriented) 
Educational group visits led by non-
prescribing facilitators for patients, 
teach patients self-management skills, 
such as goal-setting and contracting, 
and build skills to reinterpret 
symptoms 
Overall, the peer-led, 
community-based program 
was associated with medium-
term improvements in self-
efficacy, health status, and 
utilization; and these effects 
may persist long-term 
2 fairs, 1 
poor, 1 NA 
(GRADE) 
(Rydwik 
et al., 
2004) 
NA 
1989-2000 
16 RCTs Institutional 
elderly 
patients 
Age ≥70 
Physical training 
(organisational) 
  
Physical performance: muscle 
strength, mobility, gait, ADL, 
balance, endurance, rang of motion 
A positive effect of physical 
training on muscle strength 
and mobility; moderate 
evidence for an effect on 
range of motion; and 
contradictory evidence 
regarding gait, activities of 
daily living, balance and 
endurance  
An average 
of 54 points 
out of a 
maximum 
of 100 
(Cochrane) 
(Dennis 
et al., 
2013) 
US 
2008 
1 About 30% of 
demonstration 
enrolees were 
aged 65 or 
younger, and 
~9% were age 
85 or over 
Telephone health 
coaching 
(patient-oriented) 
Specific DM services include 
educating patients about their medical 
conditions, helping patients adhere to 
physicians’ treatment plans, and 
improving patients’ self-care skills 
Some improvement in quality 
of care measures, medication 
adherence, satisfaction, health 
services use and cost, but not 
statistically significant  
NA 
(de Bruin 
et al., 
US, Canada, 
Australia, 
28 
14 RCTs, 8 
Hospital, 
community 
Comprehensive 
care program 
Enhanced care initiatives,  
Integrated services for frail elders, 
Moderate evidence for 
comprehensive care on 
6 with  
score of 0, 6 
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2012) UK, Italy, 
Norway. 
1995-2011 
pretest-post-
test studies, 5 
controlled 
clinical trials, 
3 cluster 
RCTs, 2 post-
test only 
studies, 1 case 
control study 
and home 
care, and 
specialized 
clinics, 
managed care 
organizations 
 
(organisational 
and patient-
oriented) 
guided care, transitional care service 
model, outpatients geriatric 
evaluation and management clinic, 
rural home care project, older 
hospitalized patients’ discharge 
planning and in-home follow-up 
protocol, integrated multidisciplinary 
advocacy program, integrated care 
for older people, home telehealth 
care, geriatric assessment service, 
nurse care management system, after 
discharge care management of low-
income frail elderly,  nurse physician 
collaborative partnership, geriatric 
resources for assessment and care of 
elders. Multi-disease care 
management program, frail elderly 
community-based care management 
project, chronic disease self-
management program, health 
enhancement project, telecom care, 
transitional care intervention, 
geriatric evaluation management unit, 
geriatric evaluation and management, 
geriatric home hospitalization 
service, disease state management 
program 
inpatient healthcare utilization 
and healthcare costs, health 
behaviour of patients, 
perceived quality of care, and 
satisfaction of patients and 
caregivers. Insufficient 
evidence was found for a 
beneficial effect of 
comprehensive care on health-
related quality of life in terms 
of mental functioning, 
medication use, and outpatient 
healthcare utilization and 
healthcare costs 
 
with score 
of 1, 10 
with score 
of 2, 3 with 
score of 3, 7 
with score 
of 4, 1 with 
score of 5, 1 
with score 
of 6 (sum-
score of 6) 
(Hopman 
et al., 
2016) 
US, Canada,  
2011-2013 
3 
2 RCTs, 1 
cluster RCTs 
Hospital and 
primary health 
care setting 
Comprehensive 
care program 
(organisational 
and patient-
oriented) 
Community resources, self-
management program, delivery 
system design, clinical information 
system, decision support 
Can reduce length of hospital 
stay, decrease unplanned 
charges and total charges, 
Improve the health-related 
quality of life, and decrease 
costs 
2 good 
quality 
CDSM: Chronic disease self-management programs; ADL: activities of daily living
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Patient-oriented self-management is being increasingly recognized as a key intervention for patients 
with multimorbidity. Four systematic reviews synthesised qualitative evidence on the identification of 
patients’ living experience with multimorbidity (Coventry et al., 2015); patients’ perceptions on 
facilitators and barriers associated with multimorbidity management(Koch et al., 2015; Liddy et al., 
2014); and facilitators, and barriers in priority setting and decision-making (Bratzke et al., 2015). We 
summarized the evidence as shown in Figure 3, depicting the self-management process, the 
facilitators and barriers in the managing process, and external and internal factors influencing the 
priority setting and decision making process. 
 
Figure 3. Summary of the qualitative evidence on self-management process, priority setting and 
decision making in multimorbidity.  
3.6 Others  
3.6.1 Including multimorbidity in clinical and interventional trials 
Patients with multimorbidity are routinely excluded from many trials and guidelines, however, the 
trial reporting and presentation may impact on the external validity of trials. Kenning and colleagues 
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evaluated 164 unique trials on self-management and found that 60% of trials excluded patients with 
forms of multimorbidity, with reasons poorly described or identified (Kenning et al., 2014). In the 
trials that considered multimorbidity, only 35% reported multimorbidity in their patient sample, and 
few trials explored the impact of multimorbidity. Trials need to be more inclusive of patients with 
multimorbidity and analyse the effects of multimorbidity on outcome, in order to improve the external 
validity of results for clinical populations. 
3.6.2 Multimorbidity at the end of life 
Most patients suffered from more than five severe comorbidities in the last 6 month of life (Van 
Nordennen et al., 2014), with polypharmacy a key issue. Van Nordennen and colleagues reviewed the 
decision making about medication use for comorbid diseases at the end of life. The findings suggest 
that to avoid inappropriate medication use in end-life-care patients, geriatric care providers need to 
consider goals of care, treatment targets, remaining life expectancy, time until benefit, number needed 
to treat to harm, and adverse drug reactions when making decisions. Meanwhile, medication that does 
not benefit the patients in any way should be avoided, such as statins, antihypertensive agents, 
antihyperglycaemic agents, anticoagulants and antibiotics. The aim of medication use at the end of 
life should be for symptom control.  
4. Discussion  
4.1 Summary of evidence 
There is a challenge to synthesize a comprehensive body of evidence in a single overview, however, 
this work is valuable and timely during the transition from the era of “single chronic disease medicine” 
to the era of “multimorbidity medicine” (Fabbri et al., 2015; Tinetti et al., 2012). In this overview, we 
identified 53 systematic reviews that focused on multimorbidity and synthesised the evidence by 
research topics. The main findings of this overview can be summarized as below: 
 Three major definitions were detected from three major perspectives: epidemiology and 
public health, long term care and family medicine in primary care, and clinicians and patients 
in daily clinical practice.  
 The prevalence of multimorbidity may range from 3.5% to 100%, increasing with the increase 
in age, with an S-shaped curve by age detected in the general population.  
 Cardiovascular and metabolic disease, mental health related problems, and musculoskeletal 
disorders were the main three disease patterns. Common disease combinations are: depression, 
hypertension, diabetes, arthritis, asthma, and osteoarthritis comorbid with other conditions; 
the most common diseases included in multimorbidity were: diabetes, heart disease, cancer, 
hypertension, depression, COPD, stroke, arthritis/osteoarthritis, osteoporosis, and asthma. 
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 Four groups of risk factors of multimorbidity were identified: biomedical and individual 
factors, health behaviours, socioeconomic characteristics, and social and environment factors. 
 Multimorbidity associated outcomes, such as mortality, disability and functional decline, 
quality of life, health care use and cost, “Do Not Resuscitate” orders decision making process, 
and patients’ safety were assessed by various systematic reviews. 
 Patients are often excluded in clinical decision making. Most guidelines did not take into 
account patients with multimorbidity. 
 Patients with multimorbidity are usually associated with polypharmacy, with topics on 
definition, prevalence, patterns, risk factors, health outcomes, and interventions on 
polypharmacy reviewed. 
 Interventions on multimorbidity were varied. Following Cochrane Effective Practice and 
Organisation of Care (EPOC) methodology, all interventions could be categorized into either 
organizational (care and case management, nursing home, transitional care, and physical 
training) or patient-oriented (self-management, disease management, educational groups 
visits, and telephone health coaching).  Some improvement in clinical outcomes, satisfaction, 
health services use and cost outcomes were detected from both organisational and patient-
oriented interventions. The process, facilitators and barriers in the managing and decision 
making on self-management were evaluated using qualitative research synthesis.   
4.2 Strengths and limitations of the overview  
To our knowledge this is the first overview of systematic reviews to assess current evidence on 
multimorbidity. There are some strengths and limitations associated with this overview. An overview 
of systematic reviews can provide a wide-perspective on the research topic. We used broader search 
strategies and inclusion criteria than most included systematic reviews. Qualitative research (Bratzke 
et al., 2015; Coventry et al., 2015; Koch et al., 2015; Liddy et al., 2014) and systematic reviews on 
guidelines (Lugtenberg et al., 2011; Wyatt et al., 2014; Young et al., 2015) were also included. 
Despite the broader approach, publication bias may be a limitation of our study. As we only 
considered systematic reviews for inclusion the most recently published primary studies may not have 
been captured. We only performed qualitative evidence synthesis because of large heterogeneity in 
the included studies and some primary studies may have been included in more than one systematic 
review. 
4.3 Implications for practice and policy  
Despite the explosion of research interest in multimorbidity, there remains limited progress in 
including multimorbidity in clinical trials and guidelines, appropriate clinical practice and decision 
making, and health policy making (Fraccaro et al., 2015; Lugtenberg et al., 2011; Sinnott et al., 2013; 
Wyatt et al., 2014).  
28 
 
As implicated from this overview, comprehensive policy and practice need multisectoral actions from 
all stakeholders, not only including health care systems, but also including public health, social, and 
environment support. This implication is consistent with WHO health aging action 2016-2020 
(Executive Board 134 A69/17., 2016). However, the first key step is making patient values visible in 
the decision making in the context of patient-centred care and person focused care (Dierckx et al., 
2013). Policy and programming should be better aligned with patients’ perspectives, and this can be 
achieved by a patient-centred approach (Liddy et al., 2014). There is a need to develop tools to 
incorporate patient’s priorities in clinical decision making and to test their effectiveness (Mangin et al., 
2016). Meanwhile, better understanding of patients’ living experience with multimorbidity is a crucial 
factor to design and deliver self-management interventions. 
Few studies have been conducted in low-and-middle-income countries (Pati et al., 2015). With the 
increasing multimorbidity related disease burden, it is urgent that we accumulate evidence on all 
aspects of multimorbidity to inform health policy making in these countries.  
4.4 Implications for research 
As suggested by all included reviews, there is a need for prospective research, especially longitudinal 
cohort studies and randomized control trials, to provide more-definitive evidence on multimorbidity 
(de Bruin et al., 2012). Few longitudinal studies based in primary care have investigated 
multimorbidity. Further large, long-term prospective studies on prevalence, disease patterns, risk 
factors, various outcomes are required to provide evidence for trials on interventions and management  
(France et al., 2012).  
How to define and measure multimorbidity is the first and key issue. Although there isn’t a uniform 
methodology to define and measure multimorbidity, standardized methods for measuring 
multimorbidity in different perspectives are needed, such as public health surveillance, clinical 
practice and patients’ perspectives (Le Reste et al., 2013; Willadsen et al., 2016). Regarding research 
in prevalence, some fundamental determinants such as setting, age, gender, geographic area have to 
be examined (Holzer et al., 2014). Much more work is needed to develop an understanding of causal 
pathways, disease patterns and trajectories of multimorbidity in longitudinal studies (Marengoni et al., 
2011; Salive, 2013).  
The evidence on the effectiveness of interventions for patients with multimorbidity was mixed. More 
research and consistent methods are needed to understand the most appropriate interventions and 
management (Bleich et al., 2015). More research is required to identify sub-groups who respond to 
these interventions (Crowe et al., 2016), and to determine which specific target groups at what 
moment will benefit from the given interventions (Hopman et al., 2016), to allow the development of 
more targeted interventions. 
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Research on new and novel health care interventions for disease treatment and management should be 
taken as priorities. Health informatics related technology is helpful in clinical decision processes 
(Fraccaro et al., 2015) and in patients management and intervention programmes (Quiñones et al., 
2014), especially aligning treatment and medication information among different specialists and 
generalists because prescriptions from multiple health care providers may conflict with each other. 
However, more research is needed to understand how to embed these with existing services (Dennis et 
al., 2013).  
5. Conclusions 
Our overview of systematic reviews summarized current evidence on multimorbidity globally, and 
some preliminary evidence was identified and recommended for further research and practice. There 
is an explosion of interest in multimorbidity, yet the existing evidence is limited. There is a need for 
prospective research, especially longitudinal cohort studies and randomized control trials, to provide 
more-definitive evidence on multimorbidity to inform clinical practice and policy making.  
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